All News

Managing fatigue, sleep, urinary symptoms and depression is key to improving cognitive function in those receiving radiation therapy for prostate cancer.

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC.

I’m a single mom with chronic lymphocytic leukemia sharing how cancer tested me but revealed my resilience, hardship and the power of speaking up.

Recently, the American Lung Association released the 2025 “State of the Air” report.

Enclosed is the 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type.

Dr. Ranjit S. Bindra discusses recent advancements for the treatment of patients with primary brain tumors during Brain Cancer Awareness Month.

With proper precautions, international travel and safeguarding an arm with lymphedema are possible. Always prioritize your health and seek medical advice.

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to immune checkpoint inhibitors.

Dr. Kara Kelly discusses specific long-term health considerations that AYA survivors of lymphoma should be aware of to best prepare for survivorship.

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the disease.

Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.

The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in advanced anal cancer.

As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.

The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant.

CX-2051 treatment demonstrated responses in patients with advanced, late-line colorectal cancer, according to interim data from the CTMX-2051-101 study.

Researchers followed patients for years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was at diagnosis.

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

Even after many cancer-free years, the fear of recurrence still lingers, and many long-term survivors struggle to keep those thoughts at bay.

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.

Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.

The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.

After walking alone in Chicago’s Cancer Survivor’s Walk, I found strength, healing and a renewed commitment to live fully and authentically — starting now.

Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.

Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.